NCT06745479Recruiting
Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
Promoting Adaptive Decision-Making in Schizophrenia Through Improved Evidence Integration: A Combined Neuroimaging and Experience Sampling Study
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if attention and ways of thinking impact decision-making and brain processes related to decision-making in people with schizophrenia or schizoaffective disorder relative to people without either condition. It will also learn how brain functioning during decision-making relates to real-world decisions made during daily life. The main questions it aims to answer are: * Does paying attention to specific information impact decision-making and brain processes? * Does thinking in a certain way according to specific 'thinking strategies' improve brain processes related to decision-making? * Does brain functioning during decision-making relate to real-world choices to engage in activities? Researchers will compare brain functioning and decision-making on computer tasks of gambling after participants have been trained to use a positive thinking strategy. They will compare what is different in the brain and behavior when participants use this strategy and when they do not. Participants will also answer brief surveys about activities and feelings for a week in their daily lives. Participants will: * Complete several hours of clinical interviewing, cognitive tests, and surveys of about symptoms, experiences, and personality * Complete computer tasks about gambling decisions during MRI brain scanning and while having their visual attention measured using eye-tracking * Complete brief surveys about their activities and feelings 5 times a day for 1 week using a cell phone. Each survey only take several minutes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- 7 Jan 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Rutgers, The State University of New Jersey
- Diseases
- Schizophrenia
- NCT number
- NCT06745479
What you commit to
- Study type: Interventional
- Planned participants: 74
- From 7 Jan 2025 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Self-disclosed or noticeable intoxication from alcohol or illicit drugs (e.g., arriving to participate in the study drunk/high)
- Electroconvulsive therapy within one month of participation.
Other illness
- Many-year history of severely disordered substance use other than nicotine/tobacco (determined via interview)
- Significant physical health disorder, robust physical health conditions, neurological disease/disorder (e.g., Parkinson's, history of strokes).
- History of traumatic brain injury, head injury resulting in loss of consciousness for an extended duration or with noted neurobehavioral consequences.
- History of seizures or epilepsy.
- Currently untreated or unstable psychiatric and medical conditions.
- Pervasive history of problematic substance use (other than nicotine, alcohol, and mild-moderate cannabis use) as defined by meeting DSM-5 criteria for a substance use disorder.
- Diagnosis of, or first-degree relative with, significant psychiatric disorder (e.g., bipolar disorder, psychotic disorder, or Cluster A personality disorder).
Other
- The following criteria apply to all subjects:
- Self-disclosure of consistent current substance use other than nicotine, alcohol, or cannabis (e.g. cocaine, heroin).
- Intellectual disability
- Contra indications for MR imaging (detailed below)
- The following additional criteria apply to subjects without schizophrenia:
Who the study is looking for
- The following criteria apply to all subjects:
- Between ages of 18-50.
- Have capacity to provide informed consent
- Fluent communication in English
- Willingness and ability to follow study requirements, as evidenced by an ability to provide written or virtual informed consent and read, and complete, study procedures.
- Cognitive ability to understand tasks and estimated IQ greater than 70.
- The following criteria apply to subjects with schizophrenia:
- 1\. Primary diagnosis of schizophrenia or schizoaffective disorder
- The following additional criteria apply to subjects without schizophrenia:
- 1\. Inclusion based on subject matched to psychiatric group based on age, sex, race/ethnicity, and education level.
Age in the registry: 18 years to 50 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Advanced Human Brain Imaging Research Coordinator of this site? Confirm its status | Piscataway | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.